We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
(-16%)
Cap. Flow
-$92.5M
Cap. Flow
% of AUM
-4.18%
Top 10 Holdings %
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$14.4M |
| 2 |
Centene
CNC
|
+$8.41M |
| 3 |
Sanofi
SNY
|
+$6.73M |
| 4 |
Eli Lilly
LLY
|
+$6.66M |
| 5 |
IQVIA
IQV
|
+$6.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$15.5M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$12.5M |
| 3 |
Johnson & Johnson
JNJ
|
+$11.1M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$10.3M |
| 5 |
Elevance Health
ELV
|
+$9.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.66% |
| 2 | Real Estate | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Acadia Healthcare
ACHC
$2.87B
| $2.41M | 0.11% |
131,200
-5,000
| -4% | -$143K |
|
127
Charles River Laboratories
CRL
$12.5B
| $2.33M | 0.11% |
18,467
-2,500
| -12% | -$375K |
|
128
Philips
PHG
$25.7B
| $2.24M | 0.1% |
70,196
+16,476
| +31% | +$583K |
|
129
Ligand Pharmaceuticals
LGND
$6.29B
| $2.23M | 0.1% |
49,036
-16,615
| -25% | -$942K |
|
|
ICPT
130
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.17M | 0.1% |
34,414
| – | – |
|
131
Arrowhead Research
ARWR
$12.1B
| $2.13M | 0.1% |
74,186
-31,212
| -30% | -$1.26M |
|
132
uniQure
QURE
$3.09B
| $2.08M | 0.09% |
43,849
-27,342
| -38% | -$1.57M |
|
|
YMAB
133
DELISTED
Y-mAbs Therapeutics
YMAB
| $2M | 0.09% |
76,548
+65,222
| +576% | +$1.89M |
|
|
ENDP
134
DELISTED
Endo International plc
ENDP
| $1.97M | 0.09% |
531,570
| – | – |
|
135
Zai Lab
ZLAB
$2.43B
| $1.93M | 0.09% |
37,523
| – | – |
|
136
Alcon
ALC
$33.9B
| $1.86M | 0.08% |
36,686
-18,683
| -34% | -$1.07M |
|
137
Axsome Therapeutics
AXSM
$11B
| $1.86M | 0.08% |
+31,591
| New | +$2.57M |
|
138
Bausch Health
BHC
$2.22B
| $1.83M | 0.08% |
118,412
-20,400
| -15% | -$492K |
|
139
Coherus Oncology
CHRS
$179M
| $1.81M | 0.08% |
111,663
-13,483
| -11% | -$249K |
|
|
TRIL
140
DELISTED
Trillium Therapeutics Inc.
TRIL
| $1.81M | 0.08% |
448,049
+1,950
| +0.4% | +$7.37K |
|
|
XRN
141
Chiron Real Estate Inc
XRN
$463M
| $1.77M | 0.08% |
34,979
+11,361
| +48% | +$765K |
|
142
Align Technology
ALGN
$12.3B
| $1.75M | 0.08% |
10,041
-12,337
| -55% | -$2.95M |
|
143
Healthcare Realty
HR
$6.96B
| $1.72M | 0.08% |
70,662
+24,662
| +54% | +$745K |
|
|
RARX
144
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.72M | 0.08% |
35,743
-20,086
| -36% | -$934K |
|
145
Quest Diagnostics
DGX
$26.2B
| $1.69M | 0.08% |
21,025
| – | – |
|
146
AnaptysBio
ANAB
$1.62B
| $1.67M | 0.08% |
118,261
| – | – |
|
147
Guardant Health
GH
$21.4B
| $1.65M | 0.07% |
23,656
+19,323
| +446% | +$1.48M |
|
148
Insmed
INSM
$28.5B
| $1.58M | 0.07% |
98,387
-66,399
| -40% | -$1.57M |
|
149
Steris
STE
$22.3B
| $1.57M | 0.07% |
11,218
-3,572
| -24% | -$534K |
|
150
Heron Therapeutics
HRTX
$95.1M
| $1.54M | 0.07% |
131,183
+71,341
| +119% | +$1.34M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.
Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.
- Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
- Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
- Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
- Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
- Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
- Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
- Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.
Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.